NCT05919771 is a clinical trial of rock climbing in Parkinson Disease, sponsored by Marymount University.

Who is sponsoring NCT05919771?

NCT05919771 is sponsored by Marymount University.

What drugs are being tested in NCT05919771?

Interventions in NCT05919771: rock climbing.

What condition does NCT05919771 study?

NCT05919771 studies Parkinson Disease.

Is NCT05919771 still recruiting?

NCT05919771 is currently completed. Last updated 22 August 2024.

Last reviewed 2024-08-22 · How we verify

NCT05919771

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Rock Climbing on Parkinson's Disease

Completed Last updated 22 August 2024

What this trial tests

trial testing rock climbing in Parkinson Disease in 32 participants. Completed in 12 August 2024.

Timeline

12 July 2023

Primary endpoint
12 August 2024

12 August 2024

Quick facts

Lead sponsor	Marymount University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	32
Start date	12 July 2023
Primary completion	12 August 2024
Estimated completion	12 August 2024
Sites	1 location across United States

Drugs / interventions tested

rock climbing

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →

Sponsor

Marymount University

Who can join

18 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is being conducted to understand the outcomes of participation in the Up ENDing Parkinson's rock climbing program (24 sessions, or twice per week for about 12 weeks) on walking \& mobility, hand strength \& dexterity, and psychological well-being in individuals with Parkinson's Disease (PD). The rock climbing sessions are administered and supervised by Up ENDing Parkinson's, and are tailored to the skill level of the participant. Participants will answer questionnaires and complete physical performance tests twice, first prior to beginning the sessions and then again after the 24 sessions have been completed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Scaling new heights: a pilot study of the impact of climbing on balance, agility, and dexterity in individuals with Parkinson's disease.
Ries JD, Cupka M, Guccione AA. · · 2025 · PMID 40026680 · DOI 10.33393/aop.2025.3339

Verify or expand the search:

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other Marymount University trials

Trials by the same sponsor.

NCT07180147 — Arlington Longitudinal Optimal Healthy Aging Study (ALOHA) · active not recruiting
NCT05558215 — Remote Balance Training for Individuals With Dementia · NA · unknown
NCT05544955 — Protein Ingestion Timing on Body Composition and Biochemical Markers in Resistance-trained Males · NA · completed
NCT03907384 — Mat Pilates and Vascular Function in Obese Females · NA · completed
NCT04509297 — Resistance Training and Milk Supplementation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05919771 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Marymount University
Last refreshed: 22 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05919771.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing